Carboplatin

Catalog No.S1215 Synonyms: JM-8, CBDCA, NSC 241240

Carboplatin Chemical Structure

Molecular Weight(MW): 371.25

Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells.

Size Price Stock Quantity  
USD 77 In stock
USD 107 In stock
USD 167 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • (A) The BRCA1-mutated TNBC cell lines MDA-MB-436 and HCC1937 were treated with CBP (10 μM) plus GEM (100 nM) combined with or without olaparib (10 μM) for the indicated times, and then, the cell viability was determined with an MTT assay. The results show data from six independent experiments expressed as the mean ± SD. p < 0.05.

    Sci Rep, 2017, 7:42319. Carboplatin purchased from Selleck.

    Detection of apoptotic responses was found to increase in epimorphin-treated  A1847 with increasing concentrations of carboplatin compared to those of the untreated controls. Data were normalized to the controls and are represented as means ± S.D. [*p<0.05 compared with control]. Images of apoptotic cells were captured at 10X magnification, with at least 3 images per well, using an upright phase-contrast microscope (T3.15A; Fisher Scientific).

    PLoS One 2012 8, e72637. Carboplatin purchased from Selleck.

  • A. MCF10A-Ras overexpressing a vector control or the gene of interest (GeneX), or MCF7 expressing a scramble or a siRNA for the geneX were treated with DMSO or with Carboplatin for 24h. Resistant colonies were allowed to grow for 2 weeks, and are then stained with Crystal Violet. B. Quantification of the results.

     

     

    Dr. Helen Sadik of Johns Hopkins University. Carboplatin purchased from Selleck.

    Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Carboplatin for 48h. Cell survival was measured by a standarad MTT assay.

     

     

    Dr. Helen Sadik of Johns Hopkins University. Carboplatin purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells.
Features A DNA synthesis inhibitor.
Targets
DNA synthesis [1]
(A2780, SKOV-3, IGROV-1, HX62 cells)
In vitro

Carboplatin exhibits an inhibitory effect on cell proliferation in a human ovarian cancer cell line panel, including A2780, SKOV3, and IGROV-1 cells with IC50 of 6.1 μM, 12.4 μM and 2.2 μM, respectively. [1] Carboplatin also show the anti-proliferative activities in lung carcinoid cell line, such as UMC-11, H727, and H835 cells with IC50 of 36.4 μM, 3.4 μM and 35.8 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Tca8113/ut  NUWweYpuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M336SFIuOjYkgJpOwG0> MnfPO|IhcA>? Mk\obY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NXSyR49MOjZzM{exNFU>
Tca8113/CBP  M163fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\LbpRmOi1{NfMAje69VQ>? NIfn[no4OiCq NUD4NmQ3cW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NGXET|gzPjF|N{GwOS=>
Tca8113/PYM  NGXM[JZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXyyMVI26oDLzszN M2rTTVczKGh? NUX3XGJzcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NUnkc2tbOjZzM{exNFU>
SKOV3 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHROlAhdWdxbXy= NF3iNVkyNTViZB?= MkL0bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHlidHnt[UBl\XCnbnTlcpRtgQ>? NILmRlkzPjF|N{C0Ny=>
SKOV3 M{XGWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\oflExNTRizsznM41t M3LCe|I1NzR6L{eyJIg> NIfOXZhqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfGy7 NY\YZWQ3OjZzMkWyO|M>
SKOV3 M1zaR2Fxd3C2b4Ppd{BCe3OjeR?= M4\4elIh|rypL33s MlrLOFghcA>? NIH3OoFqdmS3Y3XzJIFxd3C2b4Ppdy=> MWWyOlEzPTJ5Mx?=
OSA NF;kUXREdG:wb3flcolkKEG|c3H5 MmjONk42NzVizszN M2WxPZJme3WudIOgbY4hdG:5ZYKgZ49td267IH\vdo1ifGmxbjDhd{Bkd22yYYLl[EB1dyCnaYTo[ZIhSk2LMTDzbXJPSSC2cnXheI1mdnR? NICzXYIzPjFzME[yNC=>
A549 M2mzeGZ2[3Srb36gRZN{[Xl? NFHXbmwxNzJ3L{WwJO69VQ>? MUKyOEBp NUDJfmtG\G:5boLl[5Vt[XSnczDtbXIuOjB3IHX4dJJme3Orb39CpC=> MWeyOVkyPzNzNx?=
H1975 NIjPTVVHfWO2aX;uJGF{e2G7 M{DTclAwOjVxNUCg{txO NVvBU4tLOjRiaB?= M1nBd4Rwf26{ZXf1cIF1\XNibXnSMVIxPSCneIDy[ZN{cW:wwrC= M3ziWlI2QTF5M{G3
A549 Mn;0SpVkfGmxbjDBd5NigQ>? M{X0[lAwOjVxNUCg{txO NH;NR5MzPCCq MnPDeZBz\We3bHH0[ZMhdWmULUKxPEBmgHC{ZYPzbY9v NIH4RmUzPTlzN{OxOy=>
H1975 MVnGeYN1cW:wIFHzd4F6 NF\KXYIxNzJ3L{WwJO69VQ>? MnvwNlQhcA>? MlvYeZBz\We3bHH0[ZMhdWmULUKxPEBmgHC{ZYPzbY9v M4TYflI2QTF5M{G3
A549 NXPUZ|dHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrGNlUh|ryP MU[yOEBp NWP4VFBScW6qaXLpeJMh[2WubDDndo94fGh? M3rJeVI2QTF5M{G3
H1975 NF36VmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;4[40zPSEQvF2= MmHnNlQhcA>? NYTRVplqcW6qaXLpeJMh[2WubDDndo94fGh? MXOyOVkyPzNzNx?=
MDA-MB-231 MmeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrxcHQxNTJ{MDFOwIcwdWx? MmjIO|IhcA>? MVTJR|UxyqB;IEi2JO69VQ>? NIHFc3UzPTh|N{[5NS=>
T47D M{iwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXWwMVIzOCEQvHevcYw> MVu3NkBp MnrmTWM2OMLiPTC0PE46KM7:TR?= MUeyOVg{PzZ7MR?=
LCTCC MoH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{G3cWlEPTB;Mz645qCKyrWP M2DWUlI2Pzd|MU[3
MCTCC Mk[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGG1XmJKSzVyPUKuPQKBkcL3TR?= MV6yOVc4OzF4Nx?=
MegTCC MoTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUToT5U5UUN3ME20MlHjiIoEtV2= NHK1OGYzPTd5M{G2Oy=>
MonoTCC M4Hu[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\KV2ZzUUN3ME21MlbjiIoEtV2= NHLSeIQzPTd5M{G2Oy=>
MCF7 NHPLZmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7yWYk5OjBizszN NYTHeYozPzJiaB?= NUXSPYRMcW6mdXPld{Bk\WyuIHTlZZRpKG:oIFjQNe6zNWSncHzleIVlKE2FRkegZ4VtdHN? NImzPIIzPTd4OUCyOS=>
A-549  NHWy[JJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFniOHcxNjVizszN M2WwcVI1KGh? NVvmRZlRTE2VT9Mg M4P0RYlvcGmkaYTzJINmdGxiZ4Lve5RpKHOrZ37p[olk[W62bIm= M3;RTFI2PzV3Nkmw
A-549  NGHNblBCeG:ydH;zbZMhSXO|YYm= MVGwMlUh|ryP M12xfFQ5KGh? MWjEUXNQyqB? M4q2R5Npd3e|IHXhdox6KGGyb4D0c5NqeyCoZXH0eZJmeyCrbnPseYRqdmdiYnzlZoJqdmdiYX7kJINpem:vYYTpckBkd26mZX7zZZRqd25? NH7uRpczPTd3NU[5NC=>
A-549  M{HjWmZ2[3Srb36gRZN{[Xl? M1vZcVAvPSEQvF2= NFnFN5M1QCCq NXPMS21NTE2VT9Mg MUfzbI94eyCjYnXydoFvfCCvaXPyc5R2[nWuZTDkbZNzfXC2aX;u NWTYd4k4OjV5NUW2PVA>
A-549  MVLGeYN1cW:wIFHzd4F6 M17UbVAvPSEQvF2= MonIOFghcA>? NHP2cHpFVVORwrC= NXXOXpN5cW6qaXLpeJMhd2ZiY3XscEBucWe{YYTpc47DqA>? NUfqbYpNOjV5NUW2PVA>
RMG-1 NVXadWRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTJ6LkigxtEhOy54IH3nM2w> NHuzOowzPTd{NkmxNy=>
FN-RMG-1 M3L5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfCdldKSzVyPUSwMlUhyrFiND6yJI1oN0xMIN88US=> NUnHXJdZOjV5Mk[5NVM>
RMG-1-hFUT NHTDZoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3Pb5dKSzVyPUW4MlEhyrFiMj60JI1oN0x? NFrqVFAzPTd{NkmxNy=>
FN-RMG-1-hFUT MonuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mln2TWM2OD1zMUiuPEDDuSBzMz64JI1oN0x? MmmxNlU4OjZ7MUO=
CHP-134  NI[yb2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDqS4xGOSEQvF2= MkTYSG1UV8Li M{LsR4lvcGmkaYTzJJNq\26rZnnjZY51KGOnbHyg[5Jwf3SqIHPvcYJqdmWmIIfpeIghT1ONMkizNFM4OQ>? MoLGNlU3PTh2NkO=
IMR-32 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInsZ3kyKM7:TR?= M{PxWmROW00EoB?= NWPTWmRocW6qaXLpeJMhe2mpbnnmbYNidnRiY3XscEBoem:5dHigZ49u[mmwZXSge4l1cCCJU1uyPFMxOzdz Mmn3NlU3PTh2NkO=
CHP-134  MojCSpVkfGmxbjDBd5NigQ>? MXexNEDPxE4EoB?= NV;NdGl[TE2VT9Mg MlL2bY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJGdUUzJ6M{CzO|E> NHi5emszPTZ3OES2Ny=>
IMR-32 MUTGeYN1cW:wIFHzd4F6 NU\wXYxQOTBizszNxsA> NXG1UZJWTE2VT9Mg NXHNOYFmcW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKEeVS{K4N|A{PzF? NWK3d4ZlOjV4NUi0OlM>
A549 M4X2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fQd|AvOi12MECwJO69VQ>? MlTuO|IhcA>? NFqwTWlKSzVyPUGyOkDDuSB3LkCg{txO MoftNlU3OjV{NEO=
A549/CDDP NIXaSGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXG4WZI2OC5{LUSwNFAh|ryP NFzK[GY4OiCq M2LEc2lEPTB;MkSwxsDDucLiNEWuO{DPxE1? MWKyOVYzPTJ2Mx?=
H460  MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfiWnA5OjRiaB?= MUPEUXNQ NFnkN3RKSzVyPUeuPUDPxE1? MoHZNlU2QTl7OUW=
H460  NXLpZotzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmW4O{46KM7:TR?= MmT1NlQhcA>? NWWzfFhJTE2VTx?= NXjU[4g3e2ixd4OgZUBz[WSrb4PlcpNqfGm8aX7nJIVn\mWldDD0c{BZNXKjeYO= NIXsZpYzPTV7OUm5OS=>
NRK-52E MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXyeHV[PzMEoHlCpC=> MmTuTWM2OD1zMECgxtEhOTJwOTFOwG0> M3z1RlI2PTZ3NkCz
RGE M{XPSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37oZVczyqCqwrC= M3Hl[WlEPTB;MkKgxtEhPy52IN88US=> NXL6XoQ{OjV3NkW2NFM>
NRK-52E NX\xUVRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVq3NuKhcMLi NUS1TIJkUUN6ME2xO|khyrFiOT61JO69VQ>? NFTKcIUzPTV4NU[wNy=>
RGE NYjhfFJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY[3NuKhcMLi MoDMTWM5OD14MzFCtUA4NjRizszN NVLNeWlNOjV3NkW2NFM>
SK-OV-3 NFrYXnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIX4eHI4OiCq NXu3RotjUUN3ME2xNFQvQCEQvF2= M2LBdFI2PTJyMUOy
ES-2 MnzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7pO|IhcA>? MmH3TWM2OD1zND62JO69VQ>? MmGyNlU2OjBzM{K=
OVCAR-8 NYrSdG5HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rmOlczKGh? M1W3VWlEPTB;OU[uNEDPxE1? Mmm5NlU2OjBzM{K=
3AO NVvoZnczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXVO|IhcA>? M2mxeGlEPTB;NkOuOEDPxE1? NWm3TFY2OjV3MkCxN|I>
A2780 Mn:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\SWJY4OiCq NVLWUppQUUN3ME2xOFUvPyEQvF2= Mm\MNlU2OjBzM{K=
SW626 NI[5dY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYK3NkBp MnfTTWM2OD17Nz6wJO69VQ>? M{S1UVI2PTJyMUOy
OVCAR-3 M13ZSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnv2O|IhcA>? MmS5TWM2OD1|Mj62JO69VQ>? MUWyOVUzODF|Mh?=
A549 NHv6XXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDGZm5[UUN3ME2xOVEvPTZiwsGgOVMvODZizszN NWrlT3BKOjV{N{e0OlE>
4T1 M3fZcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLDTWM2OD16ND62NkDDuSB|MD6wOUDPxE1MIN88US=> NULVbXI2OjV{N{e0OlE>
BALB/3T3 MkHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGe5dGlKSzVyPUG0MlMxKMLzIE[uOlgh|ryP MUCyOVI4PzR4MR?=
B16 NX;HOnpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTZ2LkOwJOKyKDZwOEGg{txO M1rEfFI2Ojd5NE[x
DU 145 NF3UOm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTN3LkC0JOKyKDF5LkW0JO69VQ>? MlyxNlUzPzd2NkG=
FaDu MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NET3XYVKSzVyPUS1MlM6KMLzIEGxMlUxKM7:TR?= M3PlfFI2Ojd5NE[x
HCV-29T NXzSRWdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HpTGlEPTB;NEiuOVchyrFiMkKuOFkh|ryP M4r1V|I2Ojd5NE[x
HL-60 MlnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXTXZF{UUN3ME2xNU4yOCEEsTC0MlQ4KM7:TR?= M4PJZ|I2Ojd5NE[x
HT-29 MoHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml6zTWM2OD16OT6xOkDDuSBzOD64OkDPxE1? MXuyOVI4PzR4MR?=
H146 NV:1S45oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfCTWM2OD12OT62xtEyOy5zIN88US=> MlK4NlUyOjR{OEK=
H187 NWm4UY5DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnHTWM2OD1zMj63xtEzNjdizszN NWixcnFNOjVzMkSyPFI>
H128 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHyxTXlKSzVyPUGwOk41yrF7Lk[g{txO MmHkNlUyOjR{OEK=
H69 NH;LcoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPrUopKSzVyPUe2MlnDuTJ5Lkig{txO M1fEV|I2OTJ2Mkiy
H209 M2LDS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITmUXdKSzVyPUK1PE4yyrF7OT64JO69VQ>? NX2w[Vk1OjVzMkSyPFI>
DMS153 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTV5LklCtVkvOiEQvF2= MUeyOVEzPDJ6Mh?=
H526 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTdwMtMxNU44KM7:TR?= MUiyOVEzPDJ6Mh?=
DMS114 M{X3Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfZTWM2OD16NT64xtEyOi56IN88US=> M{jsWFI2OTJ2Mkiy
DMS53 M3zmWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFW4c|lKSzVyPUG0Ok4zyrF|Nj60JO69VQ>? M13yVlI2OTJ2Mkiy
HeLa NYDON21HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rLfFUuQDBizszN MULpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 M1vSU|I2OTB7M{[w
MCF-7 M3jNdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHjOU05OCEQvF2= NHzOfpFqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NVzEbGdlOjVzMEmzOlA>
MDA-MB-231 MkH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TBVFUuQDBizszN MmTQbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NHSzZ2szPTFyOUO2NC=>
CaOV3 NFX4OVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYO3NkBp M1zBZmlEPTB;OE[uNUDPxE1? M3q2WlI2ODZ6OES5
OVCAR-3 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TYWlczKGh? MVzJR|UxRTF5OT61JO69VQ>? MlLDNlUxPjh6NEm=
OVCAR-5 NEDhO45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIqzTXM4OiCq NFfUeHpKSzVyPUe1Mlch|ryP MmrhNlUxPjh6NEm=
SKOV-3 Mmn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnz1O|IhcA>? MonhTWM2OD13MESg{txO MorrNlUxPjh6NEm=
OVCAR-4 NH\2XpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{faTlczKGh? NHS1d5JKSzVyPUK5NE43KM7:TR?= M{\tfVI2ODZ6OES5
OVCAR-8 M2TwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLmTGJWPzJiaB?= Mme3TWM2OD14OUCuNkDPxE1? NUfSc3J[OjVyNki4OFk>
MA148 NXHtUG0{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPxU5E6OjRiaB?= MXnJR|UxRTh|LkdihKnDueLCiUGuOEDPxGdxbXy= NF3kUlkzPDh|MUC5NS=>
A549 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVGyOEBp NHvxRXdKSzVyPUe3Ok4x6oDLwsJihKkyNjlizsznM41t MkKzNlQ5OzFyOUG=
MDA-MB-231 NHrlTFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzxbFdDOjRiaB?= NHHRbFFKSzVyPUe0PE4x6oDLwsJihKkyNjFizsznM41t NYjiPWxHOjR6M{GwPVE>
NCI-ADR/RES  MkDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmGxNlQhcA>? MXXJR|UxRTF5NUOuNQKBkcLz4pEJOE41KM7:Zz;tcC=> NYfuZmh7OjR6M{GwPVE>
MA148 MorvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2POPFQ5KGh? NV;ldlR{UUN3ME2yPE4y6oDLwsJihKkyNjBizsznM41t NEnCVpgzPDh|MUC5NS=>
A549 MknSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV:0PEBp MlvYTWM2OD1zMUiuNQKBkcLz4pEJNU4zKM7:Zz;tcC=> MkWwNlQ5OzFyOUG=
MDA-MB-231 NHTWNYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDHOFghcA>? NUP5VppyUUN3ME2xPFMvOOLCidMx5qCKOS5{IDFOwIcwdWx? NXT4WXR[OjR6M{GwPVE>
NCI-ADR/RES  MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfEO4hCPDhiaB?= NHrWfXpKSzVyPUG5N{4x6oDLwsJihKkyNjlizsznM41t MVeyOFg{OTB7MR?=
MA148 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnoeotoPzJiaB?= MoXFTWM2OD1zMz635qCKyrIkgJmxMlIh|rypL33s NIXyTI0zPDh|MUC5NS=>
A549 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonMO|IhcA>? M3HtemlEPTB;NkSuN-KBkcLz4pEJNU4yKM7:Zz;tcC=> NVGyO49bOjR6M{GwPVE>
MDA-MB-231 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkW5O|IhcA>? NVTCXIx3UUN3ME25PU426oDLwsJihKkyNjFizsznM41t Moi3NlQ5OzFyOUG=
NCI-ADR/RES  M{LXcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWq3NkBp MkTZTWM2OD1|Nz605qCKyrIkgJmxMlch|rypL33s MkDuNlQ5OzFyOUG=
A549 NWXPboxzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUC3NkBp M2\TcGROW09? MYTJR|UxRTF3Mj60NFkh|ryP NWX0T3ZROjR5MkGzNlM>
NCI-H157 NXnIRlJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUG3NkBp NWjBXZljTE2VTx?= MlPpTWM2OD16OT65O|ch|ryP NYDWd3NIOjR5MkGzNlM>
PC9 NFTyUm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Xo[lczKGh? M1mzTGdEPTB;N{GuOuKyQS53INM1US=> Mn3ENlQ3OTh6MEm=
A549  MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnn0O|IhcA>? NGfT[WNISzVyPUGzOuKyOzFwNjFCuW3DqA>? MoLxNlQ3OTh6MEm=
PC9 MYnBdI9xfG:|aYOgRZN{[Xl? MmTkNVAxKML3TR?= MnTuO|IhcA>? MUXpcoR2[2W|IHHwc5B1d3Orcx?= M1;XZlI1PjF6OEC5
A549  MoLTRZBweHSxc3nzJGF{e2G7 M1r2WlExOCEEtV2= M3r4RVczKGh? Ml3wbY5lfWOnczDhdI9xfG:|aYO= MVqyOFYyQDhyOR?=
A549 NGPsRm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jubVI1KGh? NWnBV415UUNzME2xMlQ4PiCwTR?= NFToT5czPDN7NkSzOy=>
H1299 M4PYNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnxdWUzOjRiaB?= M1m1PGlEOTB;MD60OFMhdk1? NUj6S4E4OjR|OU[0N|c>
HCC15 NHPhfIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\ud|I1KGh? M{LETWlEOTB;MD6zOFYhdk1? NYWxPG03OjR|OU[0N|c>
H157 M3THXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHHZ2pnOjRiaB?= NFL3fnpKSzFyPUCuPFEhdk1? MXiyOFM6PjR|Nx?=
A2780 NXT3cJZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTF2LkFihKnDueLCiUGuOEDPxE1? MoLpNlQzODl4OUO=
A2780cisR M4\TPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTOW2dKUUN3ME20PE466oDLwsJihKk{NjlizszN NGmycm4zPDJyOU[5Ny=>
A2780ZD0473R MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TqcWlEPTB;NkSuOwKBkcLz4pEJN{4zKM7:TR?= NEi4TXgzPDJyOU[5Ny=>
SKOV-3 M2rvPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXe4UVZ[UUN3ME20N{416oDLwsJihKk{NjlizszN MUGyOFIxQTZ7Mx?=

... Click to View More Cell Line Experimental Data

In vivo In A2780 tumor xenografts, Carboplatin (60 mg/kg via i.p.) given as single agents shows a modest antitumor effect with the relative tumor volumes on day 6 of 8.4 compared to the control of 11.9, and the day 6 tumor weights relative to control (T/C) of 67%. [1] For the VC8 (Brca2-deficient) xenografts, Carboplatin treatment delays tumor growth and reduces tumor mass by 42% compared to the vehicle group. [3]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: A2780, SKOV3, IGROV-1 and HX62
  • Concentrations: 0-200 μM
  • Incubation Time: 72 hours
  • Method:

    3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assays: Exponentially growing A2780, SKOV3, IGROV-1 and HX62 ovarian cancer cells are plated in 96 well plates. A range of drug concentrations are added and the plates are incubated for 72 hours to allow for 3–4 doubling times. Each experiment is carried out in triplicate. Sulforhodamine B (SRB) assays: Exponentially growing A2780 cells are plated in 96 well microtitre plates. For experiments studying concomitant exposure, cells are exposed to increasing concentrations of both drugs for 96 hours. For experiments studying the effect of sequence of exposure to 17-AAG or carboplatin cells are exposed to increasing concentrations of 17-AAG or carboplatin for 24 hours. A period of 24-hour exposure to the first agent is chosen so that the A2780 cells would be exposed to the first drug for at least one doubling time (18-24 hours). The cells are then washed with sterile phosphate buffered saline and the medium is replenished. Following this, the second drug (to which the cells are not exposed to in the first 24 hours) or medium is added for 96 hours. All experiments are carried out in triplicate. The results of combination studies are analyzed using the well-established principles of median effect analysis method. The effects of the combination are calculated using an in-house spreadsheet.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: The A2780 human ovarian cancer cell line is grown as a subcutaneous xenograft in female athymic NCr nude mice (nu/nu) in each flank.
  • Formulation: Carboplatin is dissolved in 43% ethanol, 33% polypropylene glycol and 24% cremaphor diluted 1:7 with sterile water.
  • Dosages: ≤60 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro Water 14 mg/mL warmed (37.71 mM)
DMSO Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
water
For best results, use promptly after mixing.
14mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 371.25
Formula

C6H12N2O4Pt

CAS No. 41575-94-4
Storage powder
in solvent
Synonyms JM-8, CBDCA, NSC 241240

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01828736 Completed Recurrent Bladder Cancer|Stage IV Bladder Cancer|Transitional Cell Carcinoma of the Bladder Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie|Roche Pharma AG February 9, 2004 Phase 2
NCT02124902 Recruiting Triple Negative Breast Neoplasms Washington University School of Medicine July 7, 2014 Phase 2
NCT02941523 Not yet recruiting Cancer Noxopharm Limited March 6, 2017 Phase 1|Phase 2
NCT01352962 Active, not recruiting Urethral Neoplasms|Neoplasms, Urethral|Ureter Cancer|Cancer of the Urethra|Urethral Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 5, 2011 Phase 1
NCT03032614 Not yet recruiting Breast Cancer Stage IV|Ovarian Cancer|BRCA1 Mutation|BRCA2 Mutation The University of Texas Health Science Center at San Antonio March 31, 2017 Phase 2
NCT01419548 Withdrawn Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 29, 2011 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can you advise what solvent to use and the concentration for S1215 for in vitro use?

  • Answer:

    DMSO will affact the activity of platinum agents. For in vitro use, according to our experience in dissolving this compound, we didn't find any solvent can dissolve it alone, but S1215 can be dissolved in co-solvent ethanol:water=1:2 at 15 mg/ml. We didn't test the stablility of the drug in such vehicle, so it is recommended to prepare the solution just before use.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Carboplatin | Carboplatin supplier | purchase Carboplatin | Carboplatin cost | Carboplatin manufacturer | order Carboplatin | Carboplatin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID